Minimally invasive pelvic exenteration for gynaecological malignancy: A single-centre case series and review of the literature
- PMID: 35584578
- DOI: 10.1016/j.ejogrb.2022.05.003
Minimally invasive pelvic exenteration for gynaecological malignancy: A single-centre case series and review of the literature
Abstract
For those with certain recurrent gynaecological cancers where primary management such as chemo-radiotherapy has failed, or in cases of recurrence following primary surgery, pelvic exenteration (PE) is considered the only curative option. Whilst initially considered a morbid procedure, improved surgical techniques, advancing technology, and nuanced reconstructive options have facilitated more radical resections and improved morbidity and mortality. Open PE remains the gold standard approach, however, minimally invasive techniques for PE may lessen morbidity whilst achieving the same oncological outcomes. The objective of this study was to assess the feasibility and safety of minimally invasive PE with a laparoscopic or robot-assisted approach. We also performed a review of the literature on robot-assisted PE which has not been widely reported for cases of recurrent gynaecological malignancy. Between 2015 and 2021six minimally invasive PE were performed. All patients underwent extensive multi-disciplinary assessment and counselling pre-operatively. Patient characteristics, treatment indication, perioperative data, short-term complications, and histological outcomes were recorded. There were two anterior exenterations, three posterior exenterations and one total exenteration performed. The primary cancer stage varied from stage 1a-3b. Five out of six patients had pre-operative chemo-radiotherapy. The average operative time (including surgical docking) was 600 min. Mean blood loss was 400 mL and the average length of stay was eight days. Enhanced recovery practices were used where possible. There were no intraoperative complications and one major post-operative complicationwhich was breakdown of an inferior gluteal artery perforator flap perineal reconstruction. All patients had negative margins at post-operative histopathology. All patients are alive and recurrence free at follow-up, but long-term outcome data is needed. This initial case series suggest that minimally invasive pelvic exenterationcan feasibly be performed in place of open pelvic exenteration. Furthermore, our findings suggest this may be a safe alternative as we report similar findings to the existing literature, however no firm conclusions can be drawn at such an early stage. Long term follow-up data and a larger cohort study will be needed to establish non-inferiority to open PE.
Keywords: Minimal access surgery; Pelvic exenteration; Recurrent gynaecological malignancy; Robotic surgery.
Crown Copyright © 2022. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Utilization and perioperative outcome of minimally invasive pelvic exenteration in gynecologic malignancies: A national study in the United States.Gynecol Oncol. 2021 Apr;161(1):39-45. doi: 10.1016/j.ygyno.2020.12.036. Epub 2021 Jan 3. Gynecol Oncol. 2021. PMID: 33402282
-
Feasibility of robotic platform to perform R0 resection for locally advanced multi-visceral pelvic malignancy: an institutional experience on outcomes of robotic pelvic exenteration.Langenbecks Arch Surg. 2023 Dec 16;409(1):9. doi: 10.1007/s00423-023-03206-7. Langenbecks Arch Surg. 2023. PMID: 38102305
-
Minimally Invasive Pelvic Exenteration for Gynecologic Malignancies: A Multi-Institutional Case Series and Review of the Literature.J Minim Invasive Gynecol. 2019 Nov-Dec;26(7):1316-1326. doi: 10.1016/j.jmig.2018.12.019. Epub 2019 Jan 4. J Minim Invasive Gynecol. 2019. PMID: 30611973 Review.
-
Short- and long-term outcomes following pelvic exenteration for gynae-oncological and colorectal cancers: A 9 year consecutive single-centre cohort study.Int J Surg. 2017 Jul;43:38-45. doi: 10.1016/j.ijsu.2017.05.037. Epub 2017 May 19. Int J Surg. 2017. PMID: 28529192
-
Primary flap closure of perineal defects to avoid empty pelvis syndrome after pelvic exenteration in gynecologic malignancies: An old question to explore a new answer.Eur J Surg Oncol. 2024 Feb;50(2):107278. doi: 10.1016/j.ejso.2023.107278. Epub 2023 Dec 18. Eur J Surg Oncol. 2024. PMID: 38134482 Review.
Cited by
-
Organ-sparing central pelvic compartment resection for the treatment of vulvo-vaginal melanomas.Melanoma Manag. 2024 Jan 12;10(3):MMT66. doi: 10.2217/mmt-2023-0001. eCollection 2023 Sep. Melanoma Manag. 2024. PMID: 38229953 Free PMC article. Review.
-
The Role of Pelvic Exenteration in Cervical Cancer: A Review of the Literature.Cancers (Basel). 2024 Feb 18;16(4):817. doi: 10.3390/cancers16040817. Cancers (Basel). 2024. PMID: 38398208 Free PMC article. Review.
-
Survival as a clinical outcome and its spiritual significance in a cohort of patients with advanced central pelvic neoplastic disease undergoing total pelvic evisceration: a poorly debated issue.Front Med (Lausanne). 2023 Jun 9;10:1173687. doi: 10.3389/fmed.2023.1173687. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37359011 Free PMC article.
-
Robotic versus open and laparoscopic pelvic exenterations for pelvic cancer: a multicenter propensity-matched analysis in Japan.Surg Endosc. 2024 Aug;38(8):4390-4401. doi: 10.1007/s00464-024-10966-w. Epub 2024 Jun 17. Surg Endosc. 2024. PMID: 38886231
-
Urological outcomes following pelvic exenteration for non-urological malignancies.Heliyon. 2024 Apr 12;10(8):e29640. doi: 10.1016/j.heliyon.2024.e29640. eCollection 2024 Apr 30. Heliyon. 2024. PMID: 38644885 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources